Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
Triple-negative breast cancer (TNBC) represents a major therapeutic challenge due to its heterogeneous and aggressive phenotype, and limited target-specific treatment options. The trophoblast cell surface antigen (Trop-2), a transmembrane glycoprotein overexpressed in various cancers, has emerged as...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2024-08-01
|
| Schriftenreihe: | Frontiers in Immunology |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1447280/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|